Poster Preview: ASCP 2024
Attending the 2024 ASCP Annual Meeting? Be sure to catch these upcoming poster presentations.
Source: psychiatrictimes.com
📰 Term Safety News
Term Safety News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Term Safety. Real-time updates on events, politics, business and more.
Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
KarXT demonstrated a favorable long-term metabolic profile where most patients experienced stability or improvements on metabolic parameters over 52 weeks of treatment A majority of patients ...
Bristol Myers Squibb Roland Chen Exchange Commission Schizophrenia International Research Society Term Safety Oral Session
Source: marketscreener.com
UCB Presents New Five-Year Data on BIMZELX® (bimekizumab-bkzx) in Ankylosing Spondylitis at ACR Convergence 2023
/PRNewswire/ -- UCB, a global biopharmaceutical company, today announced new long-term data from the BIMZELX® (bimekizumab) Phase 2b study BE AGILE and its...
Source: prnewswire.com
Gilead to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting® 2023
– Three Oral Presentations and 30 Posters Across HBV, HCV, HDV, and Fibrosis, Including Late-Breaking Data on Hepcludex® in HDV, Demonstrate Gilead’s Commitment to Addressing Unmet Needs for...
Foster City United States Tenofovir Alafenamide Clinical Research For Hepatitis Risk Of Development Gilead Sciences In Liver Disease
Source: marketscreener.com
Argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions
Long-term clinical trial and real-world data illustrate VYVGART® drives consistent, repeatable and clinically meaningful responses, including minimal symptom expression in generalized myasthenia...
Source: marketscreener.com
argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions
Long-term clinical trial and real-world data illustrate VYVGART® drives consistent, repeatable and clinically meaningful responses, including mini...
Source: businessinsider.com
2023 Menopause Society Annual Meeting Highlights Vasomotor Symptoms Treatment
Individuals in menopause who receive estetrol and fezolinetant show improvements in vasomotor symptoms.
United States American Menopause Society Annual Conference American Menopause Society North American Menopause Society Carbohydrate Metabolism Severe Vasomotor
Source: clinicaladvisor.com
Capricor Therapeutics Announces Late-Breaking Presentations at 28th Annual Congress of the World Muscle Society
-24-Month Open Label Extension Data from HOPE-2 Study Supports CAP-1002’s Sustained Efficacy and Safety in Treating Duchenne Muscular Dystrophy--C...
Source: businessinsider.com
Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder
Patients newly treated with REL-1017 for up to one year experienced rapid, clinically meaningful, and sustained improvements in depressive symptoms and associated functional impairmentLong-term...
Cedric Ogorman Tim Mccarthy Securities Exchange Clinical Research Program Relmada Therapeutics Inc Prnewswire Relmada Therapeutics Inc
Source: marketscreener.com
Janssen to Showcase New Insights and Commitment to Accelerating Hope and Healing for Serious Mental Illness at Psych Congress 2023
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson will showcase data from its neuropsychiatry portfolio at Psych Congress 2023. The...
United States Reina Benabou Bill Martin Janssen Pharmaceutical Companies World Health Organization Psych Congress
Source: prnewswire.com